Keyphrases
Pharmacokinetics
100%
Atorvastatin
100%
Preeclampsia Prevention
100%
Pilot Randomized Controlled Trial
100%
High-risk Pregnant Women
100%
Preeclampsia
53%
Placebo
13%
Cholesterol Levels
13%
Maternal-fetal
13%
Pharmacokinetic Parameters
13%
Umbilical Cord
13%
Safety Parameters
13%
During Pregnancy
6%
Risk Factors
6%
Clinical Trials
6%
High Risk
6%
Human Trials
6%
Pregnant Women
6%
Delivery Time
6%
Reductase Inhibitors
6%
High-risk Women
6%
Neonatal Morbidity
6%
Neonatal Mortality
6%
Maternal Morbidity
6%
Safety Data
6%
Serious Adverse Events
6%
Birth Weight
6%
Plasma Concentration
6%
Cord Blood
6%
Preterm Delivery
6%
Angiogenic
6%
Limit of Quantification
6%
Maternal Blood
6%
Infant Birth Weight
6%
Blood Lipid Profile
6%
Singleton
6%
Congenital Anomalies
6%
Risk-benefit Analysis
6%
Fetal Death
6%
Placebo Groups
6%
3-hydroxy-3-methylglutaryl-CoA Reductase
6%
U.S. Food
6%
Neonatal Death
6%
Gestational Age at Delivery
6%
Adult Cardiovascular Disease
6%
Fetal Safety
6%
Biological Plausibility
6%
Dose Escalation
6%
Renal Clearance
6%
Maternal-neonatal
6%
Drug Side Effects
6%
Pathophysiological Pathways
6%
Favorable Risk
6%
Placebo-controlled Randomized Trial
6%
Pharmacokinetic Data
6%
Safety Risk
6%
Maternal Cholesterol
6%
Pharmacology, Toxicology and Pharmaceutical Science
Preeclampsia
100%
Pravastatin
100%
Randomized Controlled Trial
100%
Pharmacokinetics
100%
Placebo
26%
Pharmacokinetic Parameter
13%
Clinical Trial
6%
Adverse Event
6%
Preclinical Study
6%
Newborn Morbidity
6%
Newborn Mortality
6%
Premature Labor
6%
Oxidoreductase
6%
Maternal Morbidity
6%
Adverse Drug Reaction
6%
Coenzyme A
6%
Congenital Malformation
6%
Fetus Death
6%
Newborn Death
6%
Cardiovascular Disease
6%